Sign In
Buy SHTDY
$10.81
+0.0100 (+0.0926%)
At Close: Jun 03, 2026
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
08:55am, Thursday, 19'th Mar 2026
BELLEVUE, WA / ACCESS Newswire / March 19, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a healthcare-focused holding company advancing innovative medical technologies, today announced that its subsidiary,
Lakeside Signs $1.5 Million Sales Agreement with Sinopharm Group Subsidiary
08:30am, Tuesday, 17'th Dec 2024
Agreement to Deliver Critical Medicines ITASCA, Ill. , Dec. 17, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based cross-border supply chain sol
Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts
08:30am, Monday, 25'th Nov 2024
ITASCA, Ill. , Nov. 25, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider with a strategic
Pandemic Accelerates China's Drive Into mRNA Treatments
11:23am, Friday, 18'th Jun 2021
Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese compan
Week In Review: WHO Close To Approving Global Use For 2 China COVID-19 Vaccines
02:00am, Monday, 10'th May 2021
The WHO approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the global pandemic. CoronaVac is the first China-developed COVID-19 vaccine
Diversifying Into Top-Ranked Sinopharm
12:30pm, Sunday, 25'th Apr 2021
There is always a bull market starting somewhere. With over-crowded U.S. indexes pushing record highs almost daily, it should be of interest to diversify into under-owned assets classes.
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
07:01pm, Sunday, 18'th Apr 2021
Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's S
Week In Review: Eluminex Raises $50 Million For Ophthalmology Drugs
01:09am, Sunday, 29'th Nov 2020
Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has filed fo
